TherapeuticsMD, Inc. (NASDAQ:TXMD) receieved a new analyst call from JP Morgan, which initiated the stock at Overweight on June 15. Analysts at Morgan Stanley, started covering the stock on September 08 with a Equal-Weight rating. The stock won favor of Oppenheimer analysts who expressed their confidence in it using an upgrade from Perform to Outperform on July 11. Oppenheimer analysts came out with bearish views on May 09 when the call was made. They think the stock is now Perform compared to to their prior call for Outperform.
TherapeuticsMD, Inc. (TXMD) grew as high as $5.02 on Thursday before closing at $5.02. The 12.56 percent rally pushed its market cap to $1.11B. The shares went down as low as $4.44 before recovering. Trading activity significantly weakened as the volume at ready counter decreased to 3,624,780 shares versus 3,932,120 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 3,500,014 shares. The stock is now 43.02% above against its bear-market low of $3.51 on December 21, 2018. It has retreated -52.59% since it’s 52-week high of $7.66 reached in June. Now the market price is down -21.44% on the year and up 31.76% YTD.
TXMD’s 50 day simple moving average (SMA 50) price is $4.5 and its 200-day simple moving average (SMA 200) price is $5.65. The company’s stock currently has a total float of 195.2M shares. Its weekly volatility is hovering around 9.86% and felt 7.84% volatility in price over a month. On the upside, the share price will test short term resistance at around $5.23. On a downside, the stock is likely to find some support, which begins at $4.62. The failure to get near-term support could push it to $4.21.
Separately, it has been reported that multiple insider activity took place at TherapeuticsMD, Inc. (TXMD). CEO Finizio Robert G sold 184,910 shares for $20,366,559 in transaction occurred on 2018/12/20. After making this transaction, the CEO owns a direct stake of 676,771 shares, worth $102,000,000, as per the last closing price. On 2018/12/18 Milligan John C.K. Iv, President/Secretary at TXMD, dumped 258,127 shares at an average price of $3.69 per share. The selling total is valued at $27,432,322.
Director, Bernick Brian had divested 183,310 shares for $6,612,371 through a trade on 2018/12/13. Following this activity, the insider holds 760,737 shares worth $33,194,102 as of recent close. Wall Street’s most bullish TherapeuticsMD, Inc. (NASDAQ:TXMD) analysts are predicting the share price to blow past $27 per share during the next 12 months. The current median share price forecast by them is $15, suggesting that the stock could increase 198.8% in that time frame. The average price target of $16 calls for a nearly 218.73% increase in the stock price.
Also, it is trading at rather expensive levels at just over 8.51x price/book and 73.58x price/sales. TXMD’s ROE is -102.1%, which is also considerably worse than the industry’s ROE of 16.93%. It’s also very liquid in the near term, with a current ratio of 7.2. The stock has a debt/capital of 0.55.
Shares of TherapeuticsMD, Inc. (TXMD) have dropped -4.5% since the company’s Mar-19 earnings report. Over the past 12 fiscal quarters, TherapeuticsMD, Inc. (NASDAQ:TXMD) has topped consensus earnings estimates in 2 quarters (16%), missed earnings in 6 quarters (50%), whereas at 4 occasion EPS met analyst expectations. TXMD last reported earnings on November 07, 2018 when it released Sep-18 results that exceeded expectations. The company raked in -$0.16 per share, -99.34% change on the same period last year. That was better than consensus for -$0.21. Revenue for the recent quarter stood at $3.47 million, down -21% on last year and below the $4.43 million predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $8.8 million to $9.19 million, which should be compared with $0 generated last year. EPS is seen in a range of -$0.16 to -$0.11, against the 0 reported a year ago.